2026 Simcyp Workshops
Advance your PBPK and model-informed drug development expertise with Simcyp workshops. Learn from experts through…
CertaraJune 11, 2026
Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study
Download this poster to see how Certara used quantitative systems pharmacology (QSP) to translate ¹⁷⁷Lu-PSMA-617…
CertaraJune 9, 2026
Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies
Explore how population PK modeling predicts absorbed dose and biologically effective dose for radioligand therapies.
CertaraJune 9, 2026
Beyond Compliance: What ICH M15 Means for the Future of Drug Development
Explore how ICH M15 is shaping regulatory expectations for Model-Informed Drug Development (MIDD), including model…
CertaraJune 9, 2026
Applying AI-Driven Biosimulation to Drug Discovery
Certara President Leif Pedersen explains how PBPK and QSP modeling, proven across 125+ FDA-approved drugs,…
CertaraJune 2, 2026
Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib
This publication reports a pooled retrospective analysis evaluating growth patterns in children with B-Raf proto-oncogene…
Dorottya Gui-BodnarMay 28, 2026
The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators
Learn how PBPK and QSP modeling support regulatory confidence, accelerate drug development, and align with…
CertaraMay 26, 2026
Certainty US 2026 recap: advancing model-informed drug development right from the start
This blog shares the highlights of our US Certainty event and explains how AI-enabled approaches…
CertaraMay 26, 2026
